Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anacor Pharmaceuticals LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is handled by examiner O DELL, DAVID K. Since there is only 1 pending office action, the company's current prosecution resources are dedicated to this individual case. This allows the legal team to focus entirely on the specific technical and legal hurdles presented by this one examiner.
The case resides within 1 distinct art unit. O DELL, DAVID K is the busiest examiner with 1 pending office action. With 1 distinct examiner and 1 distinct art unit, the company's current pharmaceutical portfolio is under a single line of review. This highly focused profile indicates a specific technical objective within the biotechnology sector. The outcome of this single pending office action will be the primary indicator of the company's current prosecution performance in the life sciences. By focusing on 1 pending office action, the company can ensure that its technical arguments are as robust as possible for this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18949024 | OXABOROLE ESTERS AND USES THEREOF | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18949024 | OXABOROLE ESTERS AND USES THEREOF | O DELL, DAVID K | 1621 | DP | Non-Final OA | — | Pending | Nov 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnacor Pharmaceuticals LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David K O Dell has the most, with 1 of Anacor Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
